Anesthesiologists flag GLP-1 use as a significant consideration in preoperative assessment
Acknowledgements The author thanks Morten Donsmark and Tine Bkdal (both Novo Nordisk A/S, Sborg, Denmark), and Kazushiro Fujiwara, and Eirik Quamme Bergan (both Novo Nordisk Pharma Ltd, Tokyo, Japan) for reviewing the manuscript, and to Andy Bond of Spirit Medical Communications Group Ltd for medical writing and editorial assistance (funded by Novo Nordisk A/S, Sborg, Denmark)
Tirzepatide Weight Loss Injections in Naperville Tirzepatide is a next-generation dual GIP/GLP-1 receptor agonist, meaning it targets two separate hormones involved in appetite regulation and blood sugar control
Zepbound is available in three forms: vial, pen, or Kwikpen
Decreased prevalence of diabetes in marijuana users: cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) III